These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 1878688)

  • 1. Monoclonal anti TNF alpha antibody in the treatment of acute GvHD refractory both to corticosteroids and anti IL-2 R antibody.
    Hervé P; Racadot E; Wijdenes J; Flesch M; Tiberghien P; Bordigoni P; Holler E; Powles M; Bourdeau M; Wilmer E
    Bone Marrow Transplant; 1991; 7 Suppl 2():149. PubMed ID: 1878688
    [No Abstract]   [Full Text] [Related]  

  • 2. Sequential use of three monoclonal antibodies in corticosteroid-resistant acute GVHD: a multicentric pilot study including 15 patients.
    Racadot E; Milpied N; Bordigoni P; Cahn JY; Plouvier E; Lioure B; Lutz P; Wijdenes J; Herve P
    Bone Marrow Transplant; 1995 May; 15(5):669-77. PubMed ID: 7670394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of acute graft versus host disease with a murine monoclonal antibody to the IL-2 receptor.
    Tiley C; Powles R; Teo CP; Treleaven J; Findlay M; Hewetson M
    Bone Marrow Transplant; 1991; 7 Suppl 2():151. PubMed ID: 1652326
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants.
    Herbelin C; Stephan JL; Donadieu J; Le Deist F; Racadot E; Wijdenes J; Fischer A
    Bone Marrow Transplant; 1994 May; 13(5):563-9. PubMed ID: 8054909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives in the prevention and treatment of acute graft versus host disease.
    Herve P
    Bone Marrow Transplant; 1991; 7 Suppl 2():117-9. PubMed ID: 1715225
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of monoclonal antibodies in vivo as a therapeutic strategy for acute GvHD in matched and mismatched bone marrow transplantation.
    Herve P; Bordigoni P; Cahn JY; Flesch M; Tiberghien P; Racadot E; Milpied N; Bergerat JP; Plouvier E; Roche C
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1692-4. PubMed ID: 1989333
    [No Abstract]   [Full Text] [Related]  

  • 7. Unrelated bone marrow transplant. Use of IL2 receptor monoclonal antibody (IL2-R-Ab) in prophylaxis of GVHD. The GEGMO Group.
    Belanger C; Esperou-Bourdeau H; Raffoux C; Gluckman E
    Bone Marrow Transplant; 1991; 7 Suppl 2():122. PubMed ID: 1878669
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of steroid-resistant acute graft-vs-host disease after allogeneic marrow transplantation with anti-interleukin-2 receptor antibody (BT563).
    Hertenstein B; Stefanic M; Sandherr M; Bunjes D; Mertens T; Arnold R
    Transplant Proc; 1994 Dec; 26(6):3114-6. PubMed ID: 7998086
    [No Abstract]   [Full Text] [Related]  

  • 9. Blockade of acute grade IV skin and eye graft-versus-host disease by anti-interleukin-2 receptor monoclonal antibody in genoidentical bone marrow transplantation setting.
    Ozşahin H; Tuchschmid P; Lauener R; Waldvogel K; Nadal D; Seger RA
    Turk J Pediatr; 1998; 40(2):231-5. PubMed ID: 9677728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation.
    Holler E; Kolb HJ; Hintermeier-Knabe R; Mittermüller J; Thierfelder S; Kaul M; Wilmanns W
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1234-6. PubMed ID: 8442099
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
    Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H
    Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of severe steroid-refractory graft-versus-host disease with IL-2R alpha chain (CD25) monoclonal antibody].
    Lu J; Xu LP; Huang XJ; Chen H; Zhang YC; Ren HY; Guo NL; Lu DP
    Zhonghua Yi Xue Za Zhi; 2003 Feb; 83(3):216-9. PubMed ID: 12812665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of an anti-interleukine 2 receptor monoclonal antibody for GvHD prophylaxis in unrelated bone marrow transplantation. GEGMO Group.
    Belanger C
    Bone Marrow Transplant; 1993; 11 Suppl 1():112-3. PubMed ID: 8448532
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease.
    Imamura M; Hashino S; Kobayashi H; Kubayashi S; Hirano S; Minagawa T; Tanaka J; Fujii Y; Kobayashi M; Kasai M
    Bone Marrow Transplant; 1994 Jun; 13(6):745-51. PubMed ID: 7920309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How should corticosteroids be used in the treatment of acute GVHD? EBMT Chronic Leukemia Working Party. European Group for Blood and Marrow Transplantation.
    Ruutu T; Hermans J; van Biezen A; Niederwieser D; Gratwohl A; Apperley JF
    Bone Marrow Transplant; 1998 Sep; 22(6):614-5. PubMed ID: 9758357
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of an anti-interleukin-2 receptor monoclonal antibody for GVHD prophylaxis in unrelated donor BMT.
    Belanger C; Esperou-Bourdeau H; Bordigoni P; Jouet JP; Souillet G; Milpied N; Troussard X; Kuentz M; Herve P; Reiffers J
    Bone Marrow Transplant; 1993 Apr; 11(4):293-7. PubMed ID: 8485477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylaxis of graft-versus-host disease in identical sibling donor bone marrow transplant by anti-IL-2 receptor monoclonal antibody LO-Tact-1.
    Ferrant A; Latinne D; Bazin H; Straetmans N; Cornet A; de la Parra B; Michaux JL
    Bone Marrow Transplant; 1995 Oct; 16(4):577-81. PubMed ID: 8528175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble CD8, IL-2 receptor, and tumor necrosis factor-alpha levels in steroid-resistant acute graft-versus-host disease. Relation with subsequent response to anti-IL-2 receptor monoclonal antibody treatment.
    Tiberghien P; Racadot E; Lioure B; Delain M; Girard A; Wijdenes J; Plouvier E; Flesch M; Cahn JY; Herve P
    Transplantation; 1991 Sep; 52(3):475-80. PubMed ID: 1910217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and novel therapies in acute GVHD.
    Ho VT; Cutler C
    Best Pract Res Clin Haematol; 2008 Jun; 21(2):223-37. PubMed ID: 18503988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daclizumab for children with corticosteroid refractory graft-versus-host disease.
    Teachey DT; Bickert B; Bunin N
    Bone Marrow Transplant; 2006 Jan; 37(1):95-9. PubMed ID: 16247417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.